211 related articles for article (PubMed ID: 29018927)
41. Diagnostic Performance of Whole-Body Diffusion-Weighted Imaging Compared to PET-CT Plus Brain MRI in Staging Clinically Resectable Lung Cancer.
Usuda K; Sagawa M; Maeda S; Motono N; Tanaka M; Machida Y; Matoba TM; Watanabe N; Tonami H; Ueda Y; Uramoto H
Asian Pac J Cancer Prev; 2016; 17(6):2775-80. PubMed ID: 27356689
[TBL] [Abstract][Full Text] [Related]
42. Tumor Identification of Less Aggressive or Indolent Lymphoma With Whole-Body 11C-Acetate PET/CT.
Tsuchiya J; Yamamoto M; Bae H; Oshima T; Yoneyama T; Miura O; Tateishi U
Clin Nucl Med; 2019 Apr; 44(4):276-281. PubMed ID: 30688736
[TBL] [Abstract][Full Text] [Related]
43. Whole-body diffusion-weighted MRI for staging lymphoma at 3.0T: comparative study with MR imaging at 1.5T.
Azzedine B; Kahina MB; Dimitri P; Christophe P; Alain D; Claude M
Clin Imaging; 2015; 39(1):104-9. PubMed ID: 25108666
[TBL] [Abstract][Full Text] [Related]
44. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.
Stéphane V; Samuel B; Vincent D; Joelle G; Remy P; Francois GG; Jean-Pierre T
Eur J Radiol; 2013 Nov; 82(11):2011-7. PubMed ID: 23932096
[TBL] [Abstract][Full Text] [Related]
45. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.
Catalano OA; Daye D; Signore A; Iannace C; Vangel M; Luongo A; Catalano M; Filomena M; Mansi L; Soricelli A; Salvatore M; Fuin N; Catana C; Mahmood U; Rosen BR
Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000
[TBL] [Abstract][Full Text] [Related]
46. A Case of Low-Grade Primary Cardiac Lymphoma with Pericardial Effusion Diagnosed by Combined 18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) Imaging and Effusion Cytology.
Fukunaga H; Tatewaki Y; Mutoh T; Shimomura H; Yamamoto S; Terao C; Totsune T; Nakagawa M; Taki Y
Am J Case Rep; 2018 Mar; 19():292-295. PubMed ID: 29535291
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma.
Ponisio MR; McConathy J; Laforest R; Khanna G
Pediatr Radiol; 2016 Aug; 46(9):1258-68. PubMed ID: 27003132
[TBL] [Abstract][Full Text] [Related]
49. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
[TBL] [Abstract][Full Text] [Related]
50. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
51. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography.
Kwee TC; van Ufford HM; Beek FJ; Takahara T; Uiterwaal CS; Bierings MB; Ludwig I; Fijnheer R; Nievelstein RA
Invest Radiol; 2009 Oct; 44(10):683-90. PubMed ID: 19724232
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
55. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
56. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
[TBL] [Abstract][Full Text] [Related]
57. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
[TBL] [Abstract][Full Text] [Related]
58. Imaging children suffering from lymphoma: an evaluation of different
Kirchner J; Deuschl C; Schweiger B; Herrmann K; Forsting M; Buchbender C; Antoch G; Umutlu L
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1742-1750. PubMed ID: 28534182
[TBL] [Abstract][Full Text] [Related]
59. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.
Schmidt GP; Schoenberg SO; Schmid R; Stahl R; Tiling R; Becker CR; Reiser MF; Baur-Melnyk A
Eur Radiol; 2007 Apr; 17(4):939-49. PubMed ID: 16951929
[TBL] [Abstract][Full Text] [Related]
60. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
